Cite
HARVARD Citation
Genovese, M. et al. (2013). OP0046 Tofacitinib, an Oral Janus Kinase Inhibitor, in a Rheumatoid Arthritis Open-Label Extension Study Following Adalimumab Therapy in a Phase 3 Randomised Clinical Trial. Annals of the rheumatic diseases. p. A65. [Online].